Welcome to our dedicated page for Neurocrine Biosciences news (Ticker: NBIX), a resource for investors and traders seeking the latest updates and insights on Neurocrine Biosciences stock.
Neurocrine Biosciences Inc (Nasdaq: NBIX) is a neuroscience-focused biopharmaceutical company whose news flow centers on clinical data, product performance and pipeline progress in movement disorders, neuropsychiatry, endocrinology and metabolic disease. The company regularly issues updates on its flagship VMAT2 inhibitor INGREZZA (valbenazine) for tardive dyskinesia and chorea associated with Huntington’s disease, including head-to-head pharmacologic studies, long-term efficacy analyses and peer-reviewed publications.
NBIX news commonly features clinical trial readouts across its pipeline. Recent releases have covered Phase 3 and Phase 4 data for INGREZZA in tardive dyskinesia and Huntington’s disease chorea, a Phase 3 study of valbenazine in dyskinetic cerebral palsy, and Phase 2 results for investigational compounds such as NBI-1070770 in major depressive disorder. Investors and clinicians can also follow updates on late-stage programs including osavampator for major depressive disorder and direclidine for schizophrenia and bipolar mania, as well as next-generation VMAT2 inhibitors and CRF-based therapies for metabolic diseases like obesity.
Another major theme in Neurocrine Biosciences news is financial and corporate reporting. The company announces quarterly net product sales for INGREZZA and CRENESSITY, provides guidance ranges for research and development and selling, general and administrative expenses, and discusses its R&D strategy at events such as its annual R&D Day and healthcare investor conferences. Management presentations at large industry meetings, including the J.P. Morgan Healthcare Conference and other investor conferences, are also highlighted in press releases.
This NBIX news page aggregates these updates so readers can quickly review earnings announcements, clinical milestones, R&D strategy briefings, investor conference appearances and key scientific publications related to Neurocrine Biosciences. For anyone tracking developments in tardive dyskinesia, Huntington’s disease chorea, classic congenital adrenal hyperplasia, neuropsychiatric disorders or emerging CRF-based metabolic therapies, the news stream provides a concise view of the company’s ongoing activities and disclosures.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Neurocrine Biosciences (NASDAQ: NBIX) has announced a conference call and webcast scheduled for May 3, 2023, to discuss its Q1 2023 financial results. The press release will be available at 4:30 a.m. PT / 7:30 a.m. ET, followed by the conference call at 5:00 a.m. PT / 8:00 a.m. ET. Interested parties can join via phone using the domestic number 800-895-3361 or the international number 785-424-1062, with Conference ID NBIX. A webcast of the call will be accessible on the company’s website, and a replay will be available for one month afterward.
Neurocrine Biosciences (NASDAQ: NBIX) will present at the Stifel 2023 CNS Days on Tuesday, March 28, 2023, at 12:30 p.m. Eastern Time. Eiry Roberts, Chief Medical Officer, and Kyle Gano, Chief Business Development and Strategy Officer, will represent the company.
The live presentation will be webcasted and can be accessed on Neurocrine's website under the Investors section. A replay of the event will be available about one hour after the presentation and archived for one month.
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced the publication of data from the RE-KINECT study, the largest real-world analysis of patients with possible tardive dyskinesia (TD). The study showed that patients aware of their involuntary movements reported significant negative impacts on their health and social functioning. An important finding was the disconnect between clinician-rated TD severity and patient perceptions. The study assessed 1,148 patients and highlighted the need for clinicians to evaluate both the presence of TD and its effects on daily life for better treatment plans. This research underlines the necessity for comprehensive assessments of the quality of life in TD patients.
Neurocrine Biosciences (Nasdaq: NBIX) announced the presentation of data from three in vitro studies regarding the dissolution performance of INGREZZA® (valbenazine) capsule contents when mixed with soft foods or delivered via G-tube. Results indicated that crushing the capsules did not affect dissolution performance compared to whole capsules. This is significant for elderly patients with tardive dyskinesia, who may have difficulty swallowing. The data will be presented at the AMDA-PALTC23 Annual Conference from March 9-12 in Tampa, Florida, demonstrating the drug's versatility in administration methods.